Articles about icosavax

Vote for Deal of the Year: Four startups raise cash and a biotech giant acquires a UW spinout

Four big startup fundraising rounds and one major acquisition in the biotech space make up the finalists in this year’s… Read More

AstraZeneca completes $1.1B acquisition of Univ. of Washington biotech spinout Icosavax

Biotech giant AstraZeneca has completed its $1.1 billion acquisition of Icosavax, a Seattle-based spinout from the University of Washington’s Institute for… Read More

AstraZeneca will pay up to $1.1B to acquire Icosavax, a Univ. of Washington biotech spinout

Seattle-based Icosavax, a spin-out from the University of Washington’s Institute for Protein Design, will be acquired by biotech giant AstraZeneca for… Read More

Icosavax posts COVID-19 vaccine data ‘below our expectations’ as shares plummet more than 60%

Seattle-based vaccine company Icosavax posted disappointing clinical data today for its experimental COVID-19 vaccine, sending its stock into a dive.… Read More

Tech Moves: Leafly announces new board ahead of SPAC merger; Amazon vets depart; and more

— Leafly announced its new six-member board of directors whose appointments will be effective after its pending SPAC merger with… Read More

Tech Moves: Bioengineer joins AI2 incubator; Icosavax adds execs, expands board; and more

— The Allen Institute for AI (AI2) added bioengineer Jenny Cronin as a principal working with entrepreneurs in AI2’s startup… Read More

Tech Moves: The Riveter’s Amy Nelson to lead new SaksWorks venture; Funko’s leadership transition

— Amy Nelson is getting back into co-working. The founder and former CEO of The Riveter announced Tuesday that she… Read More

Icosavax stock skyrockets 200% on first day of trading for newly public Seattle biotech company

Icosavax is having quite the debut as Washington state’s newest public company. Shares of the Seattle-based biotech firm surged more… Read More

Seattle’s HDT Bio to start U.S. clinical trials of its COVID-19 vaccine candidate

An experimental COVID-19 vaccine in development by Seattle-based HDT Bio will enter early-stage clinical trials in the U.S., the company… Read More

Ultrapotent, nanoparticle COVID-19 vaccine with Univ. of Wash. roots gets $173M for human trials

A project to test what’s being called an ultrapotent, second-generation COVID-19 vaccine candidate will receive up to $173.4 million to… Read More

GeekWire Awards 2021: Learn about the 5 finalists for Innovation of the Year

Innovators across the Seattle area are tackling problems big and small with a variety of breakthroughs and technologies. Whether it’s… Read More

Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology

New funding: At a moment when vaccines are on everyone’s mind, a Seattle-based biotech company that has an unusual approach… Read More

Univ. of Washington spinout Icosavax raises $51M to fight viruses with computer-designed vaccines

Seattle-based biotech startup Icosavax today scored $51 million in funding to create vaccines from artificial viruses. The Series A financing… Read More